Recurrent Glioblastoma | Norton Healthcare

Indication: Recurrent Glioblastoma

A Phase II Open-label Study Investigating the Efficacy, Safety and Pharmacokinetic Properties of OKN-007 Combined with Temozolomide in Patients with Recurrent Glioblastoma

Sub-indication: Central Nervous Syetem (CNS) Cancers

Study Type: Drug Study

Principal Investigator: Kaylyn Sinicrope, M.D.
Norton Brain Tumor Center

Sponsor: Sponsor: Oblato, Inc.

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.